@article{oai:repo.qst.go.jp:00079995,
 author = {Koto, Masashi and Ikawa, Hiroaki and Kaneko, Takashi and Hagiwara, Yasuhito and Hayashi, Kazuhiko and Tsuji, Hiroshi and Koto, Masashi and Ikawa, Hiroaki and Kaneko, Takashi and Hagiwara, Yasuhito and Hayashi, Kazuhiko and Tsuji, Hiroshi},
 issue = {9},
 journal = {Head & neck},
 month = {May},
 note = {Abstract 
Background: We evaluated the long-term efficacy and safety of carbon-ion radiotherapy (C-ion RT) for skull base chordoma, a rare neoplasm. 
Methods: Thirty-four patients with skull base chordoma who were treated with C-ion RT were prospectively enrolled and analyzed retrospectively. C-ion RT was delivered with 60.8 Gy (relative biological effectiveness [RBE]) in 16 fractions at four fractions per week. 
Results: The median follow-up period was 108 months. The 5- and 9-year local control rates were 76.9% and 69.2%, respectively. The 5- and 9-year overall survival rates were 93.5% and 77.4%, respectively. Regarding grade 3 or more severe late reactions, one patient developed a grade 3 mucosal ulcer, two developed grade 4 ipsilateral optic nerve injuries, and one developed a grade 5 mucosal ulcer at 9 years and 3 months after C-ion RT. 
Conclusion: C-ion RT with 60.8 Gy (RBE)/16 fractions is a promising treatment option for inoperable skull base chordoma.},
 pages = {2607--2613},
 title = {Long-term outcomes of skull base chordoma treated with high-dose carbon-ion radiotherapy.},
 volume = {42},
 year = {2020}
}